Medigene AG: Additional European patent granted for Medigene's DC vaccine platform
Business news for the stock market
Martinsried/Munich (08.01.2019) - Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported today that an additional European Patent was granted for its dendritic cell (DC) vaccine platform.
The European Patent EP2918673 covers an isolated mature dendritic cell or an isolated population of mature dendritic cells obtainable by a method for in vitro maturation as e.g. disclosed in the patent and has a life-span until 2027. Medigene holds an exclusive license to the patent [...]
read full post from firmenpresse